
    
      Micafungin (a new class of antifungal drugs) is compared to fluconazole (current standard
      treatment) in the treatment of patients with serious fungal infections (invasive candidiasis
      and candidemia) to determine its efficacy and safety. Patients, both male and female, aged
      over 16 and with confirmed disease by the doctor could be recruited and evaluated.
    
  